- English (USA)
- English (UK)
- English (India)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
COSMO Pharmaceuticals SA (COPN)
COSMO Pharmaceuticals SA stock price live, this page displays SIX COPN stock exchange data. View the COPN premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the COSMO Pharmaceuticals SA real time stock price chart below.
What Is the COSMO Pharmaceuticals SA Stock Price Today?
The COSMO Pharmaceuticals SA stock price today is 75.80.
What Is the Stock Symbol for COSMO Pharmaceuticals SA?
The stock symbol for COSMO Pharmaceuticals SA is "COPN."
What Stock Exchange Does COSMO Pharmaceuticals SA Trade On?
COSMO Pharmaceuticals SA is listed and trades on the Switzerland stock exchange.
Is COSMO Pharmaceuticals SA a Good Stock to Buy?
Determining whether COSMO Pharmaceuticals SA—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the COPN quote. (ISIN: NL0011832936)
What Is the COSMO Pharmaceuticals SA Stock Price Today?
The COSMO Pharmaceuticals SA stock price today is 75.80.
What Is the Stock Symbol for COSMO Pharmaceuticals SA?
The stock symbol for COSMO Pharmaceuticals SA is "COPN."
What Stock Exchange Does COSMO Pharmaceuticals SA Trade On?
COSMO Pharmaceuticals SA is listed and trades on the Switzerland stock exchange.
Is COSMO Pharmaceuticals SA a Good Stock to Buy?
Determining whether COSMO Pharmaceuticals SA—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the COPN quote. (ISIN: NL0011832936)
75.80
-3.20(-4.05%)
Closed·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
75.80
80.20
52 wk Range
41.60
129.40
COPN is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
75.8080.20
52 wk Range
41.60129.40
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
(2.53%)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
(2.53%)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
COPN Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Analysts Sentiment
Strong Buy
Price Target
116.59
Upside
+53.82%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Has raised its dividend for 5 consecutive years
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell
Cosmo Pharmaceuticals N.V., a life sciences company, develops and manufactures pharmaceuticals and contracts for gastroenterology, dermatology, and health tech in Ireland and internationally. The company offers GI Genius, a computer-assisted system that uses artificial intelligence in real time to detect colorectal lesions; Winlevi, a prescription medicine used on the skin to treat acne vulgaris; Lialda/Mezavant/Mesavancol, a once-daily mesalamine tablet approved to help get active, mild to moderate ulcerative colitis into remission; Uceris/Cortiment, an oral tablet formulation that delivers budesonide directly to the lumen of the colon; Eleview, an injectable composition to allow endoscopists with excision of gastrointestinal lesions; Lumeblue, a diagnostic drug for the visualisation of colorectal lesions during colonoscopies; Aemcolo/Rifamycin, a pharmaceutical drug product in form of tablets that is approved for the treatment of travelers’ diarrhoea; and Clascoterone, which is in phase-3 clinical trial for the treatment of male pattern hair loss. It is also developing novel UC treatment, which is in phase-2 clinical trial for the treatment of distal inflammatory bowel disease/distal ulcerative colitis/proctitis; BAD Treatment (CB-01-33), which is in phase-2 clinical trial for the treatment of colesevelam formulation/bile acid diarrhea; and CB-03-10, which is in phase-1 clinical trial for the treatment of oncology solid tumors, as well as provides Cosmo’s AI technology, a GI Genius intelligent endoscopy system. The company was founded in 1997 and is headquartered in Dublin, Ireland.
Compare COPN to Peers and Sector
Metrics to compare | COPN | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipCOPNPeersSector | |
|---|---|---|---|---|
P/E Ratio | −373.3x | 19.5x | −0.5x | |
PEG Ratio | 3.63 | 0.55 | 0.00 | |
Price/Book | 2.8x | 2.6x | 2.6x | |
Price / LTM Sales | 12.9x | 3.2x | 3.1x | |
Upside (Analyst Target) | 67.4% | 24.8% | 57.5% | |
Fair Value Upside | Unlock | 20.1% | 8.6% | Unlock |
Analyst Ratings
5 Buy
0 Hold
0 Sell
Ratings:
5 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 116.59
(+53.82% Upside)
Earnings
Latest Release
Jul 23, 2025
EPS / Forecast
-0.13 / 1.30
Revenue / Forecast
51.72M / --
People Also Watch
FAQ
What Is the COSMO Pharma (COPN) Stock Price Today?
The COSMO Pharma stock price today is 75.80 CHF.
What Stock Exchange Does COSMO Pharma Trade On?
COSMO Pharma is listed and trades on the Switzerland Stock Exchange.
What Is the Stock Symbol for COSMO Pharma?
The stock symbol for COSMO Pharma is "COPN."
Does COSMO Pharma Pay Dividends? What’s The Current Dividend Yield?
The COSMO Pharma dividend yield is 2.53%.
What Is the COSMO Pharma Market Cap?
As of today, COSMO Pharma market cap is 1.23B CHF.
What Is COSMO Pharma's Earnings Per Share (TTM)?
The COSMO Pharma EPS (TTM) is -0.23.
From a Technical Analysis Perspective, Is COPN a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has COSMO Pharma Stock Split?
COSMO Pharma has split 0 times.
How Many Employees Does COSMO Pharma Have?
COSMO Pharma has 325 employees.
What is the current trading status of COSMO Pharma (COPN)?
As of Mar 22, 2026, COSMO Pharma (COPN) is trading at a price of 75.80 CHF, with a previous close of 79.00 CHF. The stock has fluctuated within a day range of 75.80 CHF to 80.20 CHF, while its 52-week range spans from 41.60 CHF to 129.40 CHF.
What Is COSMO Pharma (COPN) Price Target According to Analysts?
The average 12-month price target for COSMO Pharma is 116.59 CHF, with a high estimate of 149.34263311 CHF and a low estimate of 77.36962071 CHF. 5 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +53.82% Upside potential.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.